EMA-2023-0062-V162
Major variation for application EMA-2023-0062. Major variation: Formulation Change for Respiralimab — major revision
Variation Number
EMA-2023-0062-V162
Type
Major
Application
Change
Status
Pending
Fee
€21,777
Submitted
2024-03-11
Approved
—
Description
Major variation: Formulation Change for Respiralimab — major revision